Erratum: Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States (Neuro-Oncology (2022) 24:11 (1989-2000) DOI: 10.1093/neuonc/noac113)

In the originally published version of this manuscript, in Table 3 of the above manuscript, an error was identified with how the table was generated from the underlying databases that resulted in small errors (each <1% in magnitude) in the frequencies and corresponding percentages of: total cases, age-adjusted incidence, sex, and race/ethnicity for several tumor types. Additionally affected were the median ages at diagnoses (with interquartile ranges [IQR]) for these tumor types. Notably, the correct median age at diagnosis for WHO grade 4 IDH-mutant astrocytomas is: 47 years (IQR: 36-60). This error also affected the total count of “Glioblastoma” in Supplemental Table 1, resulting in an error of <3%. The remaining analyses of the manuscript were unaffected, the manuscript’s text was unaffected, and the manuscript’s conclusions remain unchanged. The corrected Tables are displayed below, with the corrected results denoted with bolding. The authors apologize for this error that has now been corrected. (Table Presented).